Muhammad Mamdani, PharmD, MA, MPH  
Vice President – Data Science and Advanced Analytics at Unity Health Toronto  
The Odette Chair in Advanced Analytics  
Faculty Affiliate – The Vector Institute  
Professor, University of Toronto

Dr. Mamdani is Vice President of Data Science and Advanced Analytics at Unity Health Toronto. Dr. Mamdani’s team bridges advanced analytics including machine learning with clinical and management decision making to improve patient outcomes and hospital efficiency. Dr. Mamdani is also Professor in the Department of Medicine of the Faculty of Medicine, the Leslie Dan Faculty of Pharmacy, and the Institute of Health Policy, Management and Evaluation of the Dalla Lana Faculty of Public Health. He is also adjunct Senior Scientist at the Institute for Clinical Evaluative Sciences (ICES) and a Faculty Affiliate of the Vector Institute, which is a leading institution for artificial intelligence research in Canada. Further, Dr. Mamdani is a member of the Human Drug Advisory Panel of the Patented Medicine Prices Review Board (PMPRB).

Previously, Dr. Mamdani founded the Ontario Drug Policy Research Network (ODPRN), which is among the world’s most impactful collaborations between researchers and drug policy decision-makers. He was also the Founding Director of the Li Ka Shing Centre for Healthcare Analytics Research and Training (LKS-CHART) of Unity Health Toronto and the Founding Director of the Applied Health Research Centre (AHRC) of the Li Ka Shing Knowledge Institute of Unity Health Toronto, which is Toronto’s leading academic research organization focused on the design and implementation of multicentre clinical research initiatives. In 2010, Dr. Mamdani was named among Canada’s Top 40 under 40. Prior to joining the Li Ka Shing Knowledge Institute and Unity Health Toronto, Dr. Mamdani was a Director of Outcomes Research at Pfizer Global Pharmaceuticals in New York. Dr. Mamdani’s research interests include pharmacoepidemiology, pharmacoeconomics, drug policy, and the application of advanced analytics approaches to clinical problems and health policy decision-making. He has published approximately 500 research studies in peer-reviewed medical journals, including leading journals such as the New England Journal of Medicine, the Lancet, the Journal of the American Medical Association, the British Medical Journal, and Annals of Internal Medicine. His research has been cited over 30,000 times.

Dr. Mamdani obtained a Doctor of Pharmacy degree (PharmD) from the University of Michigan (Ann Arbor) in 1995 and subsequently completed a fellowship in pharmacoeconomics and outcomes research at the Detroit Medical Center in 1997. During his fellowship, Dr. Mamdani obtained a Master of Arts degree in Economics from Wayne State University in Detroit, Michigan with a concentration in econometric theory. He then completed a Master of Public Health degree from Harvard University in 1998 with a concentration in quantitative methods, focusing on biostatistics and epidemiological principles.
**Date:** November 28, 2019

**Contact information**

<table>
<thead>
<tr>
<th>Name</th>
<th>Muhammad Mamdani</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affiliations</td>
<td>Unity Health Toronto; University of Toronto; Vector Institute; Institute for Clinical Evaluative Sciences</td>
</tr>
<tr>
<td>Biographical details</td>
<td>See attached</td>
</tr>
</tbody>
</table>

**Declaration of competing interests**

All questions relate to the past 3 years (inclusive):

1. Have you accepted any of the following from an organization that has (or might have) a relationship with CMAJ now or in the future and that might gain or lose financially because of the relationship?

   a. Reimbursement for attending a symposium
      <details if yes:>
      <details if yes:>
      <details if yes:>
      <details if yes:>
      <details if yes:>
   b. Speaker fees
      <details if yes:>
   c. Fees for educational event
      <details if yes:>
   d. Research funds
      <details if yes:>
   e. Funds for a member of your staff
      <details if yes:>
   f. Consulting fees
      <details if yes:>

2. Do you hold stocks or shares in an organization that might benefit or lose from an existing relationship with CMAJ?
   <details if yes:>

3. Do you have other competing financial interests?
   <details if yes:>

4. I have the following other competing interests *(details)*:

   I have served on one-time Advisory Boards for the following companies: Neurocrine, Amgen, NovoNordisk, and Allergan

**Signature**

**Date** November 28, 2019